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epigenome editing with the crisPr (clustered, regularly interspaced, short palindromic repeats)-cas9 platform is a promising technology for modulating gene expression to direct cell phenotype and to dissect the causal epigenetic mechanisms of gene regulation. Fusions of nuclease-inactive dcas9 to the Krüppel-associated box (KrAB) repressor (dcas9-KrAB) can silence target gene expression, but the genome-wide specificity and the extent of heterochromatin formation catalyzed by dcas9-KrAB are not known. We targeted dcas9-KrAB to the hs2 enhancer, a distal regulatory element that orchestrates the expression of multiple globin genes, and observed highly specific induction of h3K9 trimethylation (h3K9me3) at the enhancer and decreased chromatin accessibility of both the enhancer and its promoter targets. targeted epigenetic modification of hs2 silenced the expression of multiple globin genes, with minimal off-target changes in global gene expression. these results demonstrate that repression mediated by dcas9-KrAB is sufficiently specific to disrupt the activity of individual enhancers via local modification of the epigenome.
Custom control over epigenetic regulation is becoming increasingly attainable with the expansion of genome engineering technologies that combine epigenetic modulators with programmable DNA-targeting platforms. Engineered zinc-finger proteins, transcription activator-like effectors and the CRISPR-dCas9 system can localize effector domains to target genomic regions in order to control epigenetic states 1-12 . In the CRISPR-dCas9 system adapted from Streptococcus pyogenes, codelivery of a single guide RNA (sgRNA) directs dCas9 binding through an 18-20-nt protospacer region complementary to the target genomic sequence [13] [14] [15] . The ease and versatility of this RNA-guided epigenome-editing platform have enabled its rapid application for designing gene regulatory networks, screening for cellular phenotypes and directing cell fate 9, [16] [17] [18] [19] [20] [21] . Site-specific epigenome engineering with the CRISPR-dCas9 system is also a promising technology for investigating the function of distal regulatory elements 9, 10 . Large-scale efforts to map the human epigenome have revealed more than 1 million DNase I-hypersensitive sites (DHSs), many of which probably act as cell-type-specific enhancers [22] [23] [24] . Epigenome editing proteins can be targeted to candidate regulatory elements in order to modify local chromatin structure and determine the role of these distal elements in influencing endogenous gene expression.
For targeted gene repression, the most commonly used effector is the KRAB domain 1, 3, 6 . When localized to DNA, KRAB recruits a heterochromatin-forming complex that causes histone methylation and deacetylation [25] [26] [27] [28] . dCas9-KRAB fusions have effectively silenced noncoding RNAs and single genes when targeted to promoter regions, 5′ untranslated regions and proximal enhancer elements 6, 9, 16, 18 . Libraries of sgRNAs targeting dCas9-KRAB to genomic regions proximal to transcription start sites have also been used for high-throughput gene-silencing screens 16 .
Unmodified dCas9 is known to bind at off-target loci containing a 5-bp seed sequence followed by a protospacer-adjacent motif 29, 30 . The potential for binding and subsequent epigenome editing by dCas9-KRAB at off-target sites has not been evaluated. Off-target activity is a particular concern given recent evidence that the addition of a KRAB domain to a targeted zinc-finger protein can dramatically increase off-target interactions 31 . Other studies also suggest that targeting the KRAB domain to genomic loci with other DNA-binding proteins can lead to long-range, stable H3K9me3 and chromatin condensation 2, [25] [26] [27] 32, 33 . If similar issues arise with the dCas9-KRAB platform, long-range epigenetic effects will convolute loss-of-function screens and the annotation of gene regulatory elements. Therefore, we sought to evaluate the genome-wide specificity of gene regulation, DNA binding and chromatin remodeling catalyzed by dCas9-KRAB targeted to an endogenous distal regulatory element.
We targeted dCas9-KRAB to the HS2 enhancer in the globin locus control region (LCR) 34 . The LCR contains five DHS enhancer regions (HS1-5) that orchestrate the expression of hemoglobin subunit genes in erythroid cells during development. Studies of HS2 have revealed fundamental mechanisms of enhancer activity such as transcription-factor binding, maintenance of chromatin accessibility, and chromatin looping to globin promoters [35] [36] [37] [38] . Here we demonstrate that targeting dCas9-KRAB to the HS2 enhancer disrupted the expression of multiple globin genes. Genome-wide analysis of dCas9-KRAB binding and repression activity established that RNA-guided synthetic repressors are highly specific for endogenous target loci. Deposition of H3K9me3 was limited to the intended HS2 region, leading to decreased chromatin accessibility at both the targeted enhancer and its associated promoters. These results demonstrate that dCas9-KRAB can alter the local epigenome of individual enhancers, and they support the use of dCas9-KRAB as a highly specific epigenome editing tool for directing cell phenotype and revealing connections between regulatory elements and gene expression.
results

dcas9-KrAB silences globin genes from a distal enhancer
To find optimal sgRNAs for repression of the HS2 enhancer by dCas9-KRAB, we designed a panel of 21 sgRNAs (Cr1-Cr21) to cover the 400-bp core of the HS2 enhancer ( Fig. 1a and Supplementary Table 1 ). Each sgRNA was transiently transfected into human K562 erythroid leukemia cells that were modified to stably express dCas9 or dCas9-KRAB ( Supplementary Fig. 1a ). The activity of each sgRNA was screened 3 d after transfection by quantitative real-time PCR (qRT-PCR) for expression of HBE1, HBG1 and HBG2 (HBG1/2), and HBB mRNA ( Supplementary  Fig. 1b-d) . Because of the sequence similarity between HBG1 and HBG2, PCR primers do not distinguish between the two transcripts. When transfected into K562 cells expressing dCas9-KRAB, most of the 21 sgRNAs caused decreased expression of HBE1 and HBG1/2. The sgRNAs had no effect on globin gene expression in unmodified K562 cells or when designed to target the IL1RN promoter as a negative control 7 , demonstrating that the effects were both HS2-and dCas9-specific. Reduced globin gene expression probably resulted from a combination of steric blocking and epigenome modification because dCas9-KRAB was more effective than dCas9 in silencing HBE1 and HBG1/2. HBB is not highly expressed in K562 cells 39 , and transient delivery of sgRNAs did not affect HBB expression. The repressive effects did not persist at 6 d after transient transfection of sgRNA expression plasmids ( Supplementary Fig. 2 ), likely because of a time-dependent reduction of the transfected DNA.
For further characterization of the mechanisms of targeted repression by dCas9 and dCas9-KRAB, four sgRNAs from the initial screen with the strongest effects on globin gene expression (Cr2, Cr4, Cr7 and Cr10) were transferred into a lentiviral vector and coexpressed with either dCas9 or dCas9-KRAB ( Fig. 1b) . Stable coexpression of each of the four sgRNAs with dCas9-KRAB substantially repressed expression of HBE1, HBG1/2 and HBB 7 d after transduction relative to codelivery of the sgRNA with dCas9 ( Fig. 1c-e ). Globin gene expression was not altered by dCas9 or dCas9-KRAB delivered alone or with an IL1RN-targeted sgRNA. As observed with transient sgRNA delivery, targeting dCas9-KRAB to HS2 decreased globin expression more than targeting dCas9 did. Moreover, stable expression of HS2-targeted sgRNAs with dCas9-KRAB, but not with dCas9, decreased HBG1/2 protein expression over 21 d ( Supplementary  Fig. 3 ). These results demonstrate that dCas9-KRAB repressors targeted by a single sgRNA can interrupt distal enhancer activity and silence the expression of multiple genes >10 kb away.
dcas9-KrAB repression is highly specific
Previous studies using multiplexed sgRNAs with dCas9-VP64 activators have established the specificity of endogenous gene activation 7, 40 . Additionally, sgRNA-mediated silencing with dCas9-KRAB is highly specific, as determined by microarray analyses in experiments targeting an endogenous promoter 9 and RNA-seq in experiments targeting a reporter gene 6 . To determine whether that specificity extends to dCas9-KRABmediated repression of an endogenous enhancer, we used RNAseq to measure the transcriptome-wide effects of targeting dCas9-KRAB and dCas9 to HS2 using the Cr4 and Cr10 sgRNAs ( Fig. 2a,b and Supplementary Fig. 4a,b) .
Compared with targeting with dCas9-KRAB alone, when dCas9-KRAB was targeted to the HS2 enhancer by either Cr4 or Cr10, the only significantly repressed genes were HBG1/2, HBE1 and HBBP1 (false discovery rate (FDR) < 0.01) ( Fig. 2a,b) . We observed a similar result when we compared the effect of targeting dCas9-KRAB to that of targeting dCas9, both codelivered with sgRNAs ( Supplementary Fig. 4a,b ). HBBP1 is a pseudogene that does not encode functional globin protein but may still be regulated by HS2. HBD expression was also reduced by targeting of dCas9-KRAB to HS2 with either Cr4 or Cr10, but the change in expression was not shown to be significant after (c-e) Repression of the HS2 enhancer was assayed by qRT-PCR of (c) HBE1, (d) HBG1/2 and (e) HBB, and fold-changes were calculated relative to nontransduced K562 cells (mean ± s.e.m.). In c-e, groups that share the same letter (A-F) are not significantly different as determined by multiway analysis of variance followed by Tukey's post hoc test; P < 0.05 (n = 3 independent experiments). npg multiple-hypothesis testing. The only significant off-target effect observed was an increase in expression of PCSK1N when dCas9-KRAB + Cr10 was compared to dCas9 + Cr10 (P = 1.6 × 10 −7 Supplementary Fig. 4b ). PCSK1N regulates processing of neuroendocrine pathway proteins and is not known to be involved in KRAB-mediated effects. No off-target gene expression differences were observed after treatment with Cr4.
When we compared samples treated with sgRNA and either dCas9 or dCas9-KRAB to untransduced controls, we detected a greater number of differentially expressed genes, varying from six to ten depending on the comparison ( Fig. 2c,d , Supplementary  Fig. 4c,d and Supplementary Tables 2-5 ). When we compared dCas9-KRAB without guide RNA to untransduced controls, we observed 29 differentially expressed genes ( Supplementary  Fig. 4e and Supplementary Table 6 ). Three genes were differentially expressed relative to untreated controls in all comparisons, with or without the presence of guide RNA or the KRAB domain. These modest off-target changes in gene expression might have been the result of lentiviral transduction, puromycin selection or dCas9 expression. Overall, these results indicate that RNAguided KRAB-mediated gene repression is highly specific, and they emphasize that the inclusion of proper controls such as dCas9-KRAB treatment without a functional sgRNA are critical to proper experimental design and interpretation.
dcas9-KrAB binding is highly specific
Previous reports have shown evidence that dCas9 promiscuously binds the genome outside of the target site 29, 30, 41 . However, recent studies have demonstrated that dCas9 and dCas9-KRAB effectors can bind specifically when targeting endogenous gene promoters 41 . Evaluating off-target localization and potential downstream effects of targeting endogenous enhancers is critical for implementing dCas9-KRAB to control cell phenotype and to investigate epigenome function. To evaluate the genomewide DNA-binding of dCas9-KRAB, we performed ChIP-seq using a Flag epitope expressed on the N terminus of dCas9 or dCas9-KRAB ( Fig. 1b) . Recruitment of dCas9 and dCas9-KRAB by Cr4 or Cr10 was highly localized to the HS2 enhancer ( Fig. 3a) , and there were no additional significant dCas9-KRAB binding sites in the human genome other than the sgRNA target site (Fig. 3b,c and Supplementary Tables 7 and 8) .
The addition of KRAB to dCas9 did not alter the strength of the binding signal ( Supplementary Fig. 5a,b) . With a genome-wide FDR < 0.05, there was one genomic window, located on chromosome 2, with a significant decrease in ChIP-seq signal for dCas9-KRAB + Cr4 versus dCas9 + Cr4 (Supplementary Table 9 ). The region contained a 5-bp protospacer seed sequence matched to Cr4 (refs. 29, 30) . No genome-wide significant changes in ChIPseq signal were observed in comparisons of dCas9-KRAB + Cr10 versus dCas9 + Cr10 ( Supplementary Fig. 5a,b) . When we compared dCas9-KRAB + Cr4 or Cr10 npg to dCas9 + Cr4 or Cr10, we observed a decrease in ChIP-seq signal at HS2, but it did not reach genome-wide significance (P = 4.5 × 10 −4 and P = 1.9 × 10 −4 for Cr4 and Cr10, respectively) ( Supplementary  Fig. 5a,b) . The decrease in Flag ChIP-seq signal at the HS2 enhancer and off-target site was perhaps due to epitope or targetsite inaccessibility after formation of the repressive complex by KRAB.
dcas9-KrAB binding disrupts transcription-factor binding
We hypothesized that targeting dCas9-KRAB to HS2 would decrease binding of endogenous transcription factors at the enhancer. The GATA2 and AP-1 transcription factors are well known to bind the HS2 enhancer and regulate globin gene expression, as confirmed in K562 cells by data from the ENCODE project 24, 42 . The binding motifs for both GATA2 and AP-1 are adjacent to the Cr4 and Cr10 sgRNA targets in the enhancer 34, 35, 42 ( Supplementary Fig. 6a ). We used ChIP-qPCR to evaluate disruption of the interactions of GATA2 and the AP-1 subunit FOSL1 with HS2 by dCas9-KRAB or dCas9. Recruiting dCas9-KRAB to HS2 with Cr4 or Cr10 significantly decreased binding of both GATA2 (Cr4, P = 0.0090; Cr10, P = 0.034; Supplementary Fig. 6b ) and FOSL1 (Cr4, P = 0.0090; Cr10, P = 0.0087; Supplementary  Fig. 6c ) compared with that in dCas9-KRAB-only controls. In contrast, localizing dCas9 to the HS2 enhancer did not significantly decrease the binding of endogenous transcription factors.
dcas9-KrAB induces histone methylation at enhancers
To investigate the epigenetic consequences of KRAB-mediated silencing, we assayed global H3K9me3 patterns by ChIP-seq ( Fig. 4) . dCas9-KRAB targeted to endogenous promoters can induce repressive histone methylation 9 . Furthermore, SETDB1, a methyltransferase recruited by the KRAB repression complex, catalyzes H3K9me3 when localized to genomic loci 27 . Codelivery of dCas9-KRAB and either Cr4 or Cr10 significantly increased the H3K9me3 signal at the target HS2 enhancer relative to delivery of dCas9-KRAB without an sgRNA (Cr4, P = 2.01 × 10 −26 ; Cr10, P = 1.15 × 10 −23 ; Fig. 4b,c, Supplementary Figs. 7a,b and 8, and Supplementary Tables 10 and 11) . The strength of the H3K9me3 ChIP-seq signal induced by dCas9-KRAB at the HS2 enhancer was comparable to that of the nearby endogenous H3K9me3 signal at sites that flanked the globin locus ( Fig. 4a) , indicating that dCas9-KRAB induced histone methylation at physiologically relevant levels. Furthermore, the H3K9me3 observed at HS2 did not spread beyond the DHSs overlapping the enhancer, covering a span of 853 bp. The effect at HS2 was specific to the KRAB domain, as no changes in H3K9me3 occurred at the enhancer when dCas9 was targeted with Cr4 or Cr10 ( Fig. 4d,  Supplementary Fig. 7c-f and Supplementary Tables 12 and 13) . For Cr4, an increased H3K9me3 signal was also observed at the immediately adjacent HS3 enhancer, and both Cr4 and Cr10 increased H3K9me3 at the DHSs between HS1 and HS2. Together, these results demonstrate that dCas9-KRAB can induce histone modifications associated with heterochromatin when targeted by sgRNAs to active enhancers.
To identify off-target H3K9me3 sites, we first compared dCas9-KRAB with either Cr4 or Cr10 to dCas9-KRAB without an sgRNA. For Cr4, ten off-target changes in H3K9me3 signal were detected, and eight of them contained a protospacer seedsequence match for Cr4 ( Fig. 4b and Supplementary Table 10 ). Only one off-target change in H3K9me3, found in IRF3, coincided with dCas9-KRAB binding by anti-Flag ChIP-seq with an FDR < 0.10 (FDR = 0.0785; Fig. 3b and Supplementary Table 7) . For Cr10, one off-target H3K9me3 site was observed near CYP17A1, and this region did not contain a match for the protospacer target seed ( Fig. 4c and Supplementary Table 11 ). Although we expected KRAB to cause only increases in H3K9me3, 5 of npg the 11 total off-target regions (45%) had decreased H3K9me3 signals. All changes in H3K9me3 signal outside the globin LCR were smaller in magnitude and less statistically significant than those at sites in the LCR (Supplementary Fig. 7a,b) .
We performed a similar analysis to identify differences in H3K9me3 when KRAB is added to dCas9. For the Cr4 guide RNA, we identified 44 off-target changes in H3K9me3 (Supplementary Fig. 7c ). Of these changes, 39 (89%) had a decrease in ChIP-seq H3K9me3 signal that we do not think was directly due to KRAB-domain activity. The off-target changes were also low in magnitude compared with changes in the LCR (Supplementary Fig. 7c,e) . We further analyzed the 20 off-target regions with the strongest statistical significance and found that 14 contained Cr4 seed sequences ( Supplementary Table 12 ). When we compared dCas9-KRAB + Cr10 with dCas9 + Cr10, we did not identify any offtarget H3K9me3 modifications ( Supplementary Fig. 7d,f and Supplementary Table 13 ). Overall, these results show that dCas9-KRAB generated H3K9me3 at the globin LCR with nearly perfect specificity, and off-target histone-modification events were typically subtle and varied depending on sgRNA target sequence. As many of the off-target H3K9me3 changes were decreases in H3K9me3 signal, it might be that these were false positives at this threshold of statistical significance. Furthermore, we did not observe any downstream effects on nearby gene expression associated with off-target H3K9me3 (Fig. 2a,b and Supplementary Fig. 4a,b) .
dcas9-KrAB decreases chromatin accessibility at enhancers
As an orthogonal measure of the specificity of epigenome editing by dCas9-KRAB, we used DNase I-hypersensitive sequencing (DNase-seq) to identify genome-wide changes in chromatin accessibility concurrent with KRAB-mediated gene silencing. Targeting dCas9-KRAB to the HS2 enhancer decreased chromatin accessibility at HS2, HS3 and the DHSs between HS1 and HS2 ( Fig. 5 and Supplementary Fig. 9a-d) , which were the same regions with increases in H3K9me3 (Fig. 4a) . We also observed decreased chromatin accessibility at the HBE1, HBG1 and HBG2 promoters ( Fig. 5b and Supplementary Fig. 9e-h) . These promoters are up to 25 kb from the targeted enhancer region, indicating that dCas9-KRAB-mediated H3K9me3 of the LCR directly affects chromatin structure at the target promoters.
The most significant and highest-magnitude changes for both Cr4 and Cr10 occurred at the HS2 and HS3 enhancers and the HBG1 and HBG2 promoters (Fig. 5f,g and Supplementary Tables 14  and 15 ). The effects on chromatin state were largely dependent on the addition of the KRAB domain to dCas9, as supported by comparisons of dCas9-KRAB to dCas9 with the same guide RNAs (Fig. 5b,c and Supplementary Figs. 9a-h and 10a-d) npg No significant effects on chromatin accessibility were found outside the globin locus, providing further evidence that dCas9-KRAB targeting has highly specific effects on the epigenome. Collectively these findings suggest substantial and highly specific changes to chromatin accessibility concomitant with gene repression and the introduction of repressive histone modifications by the targeted dCas9-KRAB.
discussion
The simplicity and efficacy of the RNA-guided CRISPR-dCas9 targeting system have the potential to transform epigenome editing into a widely used research tool, but the success of this application relies on precise editing of the epigenetic state. Programmable KRAB-fusion proteins have been used to repress enhancers up to 20 kb from a single target gene 9, 18 . In this study we expanded the capability of synthetic gene regulation by targeting dCas9-KRAB to an enhancer located 10 to 50 kb away from target genes and by comprehensively characterizing the remarkable specificity of this technology.
A recent study showed that targeting dCas9-KRAB to a putative distal enhancer silenced downstream gene expression but did not induce repressive histone marks at the target enhancer 9 .
Here we demonstrate that dCas9-KRAB can deposit H3K9me3 at endogenous enhancers, indicating that dCas9-KRAB-mediated histone methylation may be dependent on locus or cell type. We also did not find evidence that addition of the KRAB domain to dCas9 increased off-target binding, in agreement with other recent dCas9-KRAB genome-wide binding studies 41 . This is in contrast to another study of engineered zinc finger-KRAB fusion proteins 31 . The difference may be due to the distinct mechanism of protein-DNA binding versus RNA-DNA interactions mediated by dCas9 or locus-or cell type-specific effects. Overall, our findings advocate for the use of dCas9-KRAB repressors to achieve precise silencing of endogenous genomic targets.
Histone methylation induced by KRAB or HP1 has been estimated to spread up to 20 kb from the repressor binding site in synthetic reporter assays with other DNA-targeting proteins 26, 32, 33 . In contrast, with dCas9-KRAB, increases in H3K9me3 were found up to 4.5 kb away from the sgRNA target site. Furthermore, our H3K9me3 ChIP-seq data show that epigenome modification occurred only at flanking DHSs and did not span the region between those sites. That observation suggests that heterochromatin spreading induced by KRAB might not occur linearly along the genome, and instead might spread through threedimensional interactions between discrete nearby open chromatin sites. Spreading of histone methylation over long distances may therefore be site specific and dependent on three-dimensional chromatin structure at those sites.
The DNase I-hypersensitivity profiles of enhancers correlate with associated promoters 22 , and chromatin-conformation analyses have shown that the globin LCR physically interacts with HBG1, HBG2 and HBE1 in K562 cells 38 . Furthermore, forcing DNA-looping interactions with the globin LCR activates developmentally silenced embryonic and fetal globin expression 43 . When dCas9-KRAB was targeted to HS2, promoter regions of HBG1 and HBG2 also had decreased DNase-seq signal, whereas the HS1 region between HS2 and the target promoters was not affected. Additionally, HBG1 and HBG2 promoters did not have increased H3K9me3 signal. The decreased hypersensitivity observed at HBG1 and HBG2 is therefore unlikely to have been caused by heterochromatin spreading from the HS2 enhancer; instead it might be the result of disruption of long-range interactions between the promoters and the HS2 enhancer. Potential mechanisms for the disruption of DNA looping include interference with endogenous transcription-factor binding and alteration of the chromatin state of the enhancer region. Overall, these results suggest that the accessible chromatin structure and the active state of some promoters require continuous input from enhancer elements, and they support the use of dCas9-KRAB as a potential method to identify and disrupt these enhancer-promoter interactions.
The KRAB domain is distinctive from epigenome-editing effectors because, rather than catalyzing a single type of histone modification, it draws a diverse group of histone modifiers that cooperate to form heterochromatin 25, 27, 28, 32 . This broad efficacy probably contributes to the effectiveness of KRAB at silencing different types of genomic elements, including transcribed genes and proximal and distal regulatory elements 6, 9, 16, 18 . This versatility, along with the exceptional specificity demonstrated in this study, distinguishes dCas9-KRAB as a promising platform for applications such as gene therapy, cellular reprogramming and high-throughput screens of regulatory-element function and modulators of cell phenotype 16 .
methods
Methods and any associated references are available in the online version of the paper.
Accession codes. Raw RNA-seq (GSE71557), ChIP-seq (GSE70671) and DNase-seq (GSE70973) data are available in the Gene Expression Omnibus.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
nAture methods
Chromatin immunoprecipitation. ChIP experiments were performed in in biological triplicate, starting from independent cell transductions, and harvested 7 d after transduction. For each replicate, 2 × 10 7 nuclei were resuspended in 1 mL of RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS in PBS at pH 7.4). Samples were sonicated using a Diagenode Bioruptor XL sonicator at 4 °C to fragment chromatin to 200-500-bp segments. Insoluble components were removed by centrifugation for 15 min at 15,000 r.p.m. We conjugated 5 µg of anti-FOSL1 (Santa Cruz Biotechnology, sc-183), anti-GATA-2 (Santa Cruz Biotechnology, sc-9008), anti-Flag (Sigma-Aldrich, F1804), or anti-H3K9me3 (Abcam, ab8898) to 200 µl of either sheep anti-rabbit or sheep antimouse IgG magnetic beads (Life Technologies, 11203D/11201D). Sheared chromatin in RIPA buffer was then added to the antibodyconjugated beads and incubated on a rotator overnight at 4 °C. After incubation, beads were washed five times with an LiCl wash buffer (100 mM Tris, pH 7.5, 500 mM LiCl, 1% NP-40, 1% sodium deoxycholate), and remaining ions were removed with a single wash with 1 mL of TE (10 mM Tris-HCl, pH 7.5, 0.1 mM Na 2 -EDTA) at 4 °C. Chromatin and antibodies were eluted from beads by incubation for 1 h at 65 °C in immunoprecipitation elution buffer (1% SDS, 0.1 M NaHCO 3 ) followed by overnight incubation at 65 °C to reverse formaldehyde cross-links. DNA was purified using MinElute DNA purification columns (Qiagen).
ChIP-qPCR. qRT-PCR using QuantIT Perfecta Supermix was performed with the CFX96 Real-Time PCR Detection System (Bio-Rad) and the oligonucleotide primers reported in Supplementary  Table 16 . 100 pg of ChIP DNA was loaded into each reaction. The results are expressed as a fold-increase of signal at the HS2 enhancer normalized to signal at the GAPDH promoter by the ∆∆C t method.
ChIP sequencing. Illumina TruSeq adapted libraries were constructed using an Apollo 324 NGS Library Prep System with a PrepX Complete ILMN DNA Library Kit (WaferGen Biosystems). ChIP products were amplified with 15 cycles of PCR, and fragments 150-700 bp in length were selected using an AxyPrep MAG PCR Clean-Up Kit (Axygen MAG-PCR-CL-50). Libraries were sequenced using single end 50-bp reads on an Illumina HiSeq at the Duke Genome Sequencing Shared Resource. ChIP-seq analyses were executed independently for each epitope to find regions of differential Flag or H3K9me3 enrichment compared with cells treated with lentivirus encoding dCas9-KRAB without sgRNA or dCas9 with sgRNA. To account for background levels of integrated lentiviral DNA, we filtered reads aligning to the delivered lentiviral sequences from analyses using Bowtie2 (ref. 47 ). Next we used Bowtie2 to align the remaining reads to the hg19 reference genome and removed PCR duplicates using the rmdup tool from SAMtools 49 . Reads from each triplicate for each condition were combined, and peaks were called using MACS 50 . Resulting peaks from each condition with a q-value ≤ 0.05 were merged using the mergeBed tool from BEDTools 51 . The number of reads overlapping each of these peaks for each triplicate was determined using the intersectBed tool from BEDTools. Differential enrichment for each peak was evaluated from these read counts using DESeq2 (ref. 52) with an FDR cutoff of ≤0.05.
DNase I-hypersensitivity sequencing. All experiments were performed in biological triplicate, starting from independent cell transductions. Library preparation and analysis were performed as previously described with the one exception of addition of a 5′ phosphate group to oligo 1b to increase ligation efficiency 53 . For each replicate, 7 d after transduction, approximately 2.5 × 10 7 nuclei were extracted and then digested with different amounts of DNase I for 16 min at 37 °C. Reactions were terminated by the addition of 50 mM EDTA. Libraries were constructed from pooled digests as described and sequenced on the Illumina HiSeq2000 platform with 50-bp single-end reads at the Duke Genome Sequencing Shared Resource. Resulting reads were filtered for delivered vector sequences and aligned by Bowtie 54 . Peaks were called by MACS version 2 (ref. 50) , with a cutoff line at FDR < 0.01. Differential DHS sites were determined using DESeq2 (ref. 52 ).
